📊 GERN Key Takeaways
Is Geron Corp. (GERN) a Good Investment?
Geron demonstrates strong balance sheet liquidity but faces critical operational challenges with negative operating cash flow of -$62.9M despite generating $51.8M in revenue, signaling an unsustainable business model. At current cash burn rates, the company has approximately 1.1 years of financial runway despite $68.9M in cash reserves, requiring immediate achievement of cash flow breakeven or substantial revenue acceleration to avoid capital raise.
Geron shows meaningful revenue generation and improved net loss versus the prior year, but the business remains deeply unprofitable with negative operating income, negative free cash flow, and weak interest coverage. Balance sheet liquidity ratios are currently solid, yet the combination of $77.56M in cash and $111.72M in annual free cash flow burn raises concern about funding durability and the quality of growth unless margins improve quickly.
Why Buy Geron Corp. Stock? GERN Key Strengths
- Excellent liquidity position with 6.78x current ratio and 4.96x quick ratio providing near-term financial flexibility
- Established revenue stream of $51.8M demonstrates commercialized products in market
- Conservative debt structure with 0.52x debt-to-equity ratio limiting financial leverage risk
- Revenue has scaled to $135.87M, indicating commercial traction rather than a purely pre-revenue profile
- Net loss and diluted EPS improved materially year over year, suggesting operating progress
- Liquidity appears solid on the surface with a 4.66x current ratio and 3.62x quick ratio
GERN Stock Risks: Geron Corp. Investment Risks
- Severe negative operating cash flow of -$62.9M despite revenue generation indicates unsustainable unit economics and operational burn
- Unprofitable on net basis with -$3.6M net loss and -7.0% net margin showing inability to convert revenue to earnings
- Limited financial runway of approximately 13 months at current quarterly burn rate if no operational improvements achieved
- Profitability remains very weak, with -50.5% operating margin and -61.5% net margin
- Cash generation is poor, with operating cash flow of -$111.04M and free cash flow of -$111.72M
- Negative interest coverage and $119.55M of long-term debt increase financing and balance sheet risk if losses persist
Key Metrics to Watch
- Operating cash flow trend - must achieve positive OCF within next 2-3 quarters
- Revenue growth acceleration - need to demonstrate path to $100M+ revenue to support current cost structure
- Cash balance depletion rate and timing of potential capital raise requirement
- Free cash flow burn relative to cash on hand
- Operating margin improvement as revenue scales
Geron Corp. (GERN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.78x current ratio provides a solid financial cushion.
GERN Profit Margin, ROE & Profitability Analysis
GERN vs Healthcare Sector: How Geron Corp. Compares
How Geron Corp. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Geron Corp. Stock Overvalued? GERN Valuation Analysis 2026
Based on fundamental analysis, Geron Corp. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Geron Corp. Balance Sheet: GERN Debt, Cash & Liquidity
GERN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Geron Corp.'s revenue has grown significantly by 31% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.32 indicates the company is currently unprofitable.
GERN Revenue Growth, EPS Growth & YoY Performance
GERN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $39.6M | -$3.6M | $-0.01 |
| Q3 2025 | $28.3M | -$16.4M | $-0.03 |
| Q2 2025 | $882.0K | -$16.4M | $-0.02 |
| Q1 2025 | $304.0K | -$19.8M | $-0.03 |
| Q3 2024 | $164.0K | -$26.4M | $-0.04 |
| Q2 2024 | $29.0K | -$38.1M | $-0.09 |
| Q1 2024 | $21.0K | -$38.1M | $-0.07 |
| Q3 2023 | $164.0K | -$28.1M | $-0.08 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Geron Corp. Dividends, Buybacks & Capital Allocation
GERN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Geron Corp. (CIK: 0000886744)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GERN
What is the AI rating for GERN?
Geron Corp. (GERN) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GERN's key strengths?
Claude: Excellent liquidity position with 6.78x current ratio and 4.96x quick ratio providing near-term financial flexibility. Established revenue stream of $51.8M demonstrates commercialized products in market. ChatGPT: Revenue has scaled to $135.87M, indicating commercial traction rather than a purely pre-revenue profile. Net loss and diluted EPS improved materially year over year, suggesting operating progress.
What are the risks of investing in GERN?
Claude: Severe negative operating cash flow of -$62.9M despite revenue generation indicates unsustainable unit economics and operational burn. Unprofitable on net basis with -$3.6M net loss and -7.0% net margin showing inability to convert revenue to earnings. ChatGPT: Profitability remains very weak, with -50.5% operating margin and -61.5% net margin. Cash generation is poor, with operating cash flow of -$111.04M and free cash flow of -$111.72M.
What is GERN's revenue and growth?
Geron Corp. reported revenue of $51.8M.
Does GERN pay dividends?
Geron Corp. does not currently pay dividends.
Where can I find GERN SEC filings?
Official SEC filings for Geron Corp. (CIK: 0000886744) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GERN's EPS?
Geron Corp. has a diluted EPS of $-0.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GERN a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Geron Corp. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GERN stock overvalued or undervalued?
Valuation metrics for GERN: ROE of -1.6% (sector avg: 15%), net margin of -7.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GERN stock in 2026?
Our dual AI analysis gives Geron Corp. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GERN's free cash flow?
Geron Corp.'s operating cash flow is $-62.9M, with capital expenditures of $680.0K. FCF margin is -122.7%.
How does GERN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -7.0% (avg: 12%), ROE -1.6% (avg: 15%), current ratio 6.78 (avg: 2).